Market-leading Hims

1. Problem: Obesity white paper says the US is “obeseIt begins by outlining that “we are facing an urgent public health crisis.” The statistics are astonishing: - “40% of American adults” (over 0.1 billion people) are obese. - Forecast 2030:80% of American adults will be overweight. The reason for this increase is “cheap, low nutritional food, limited opportunities for physical activity, and social norms that encourage unhealthy behaviors.” In summary, obesity is a major problem.

2. Solution: Hims is in the weight loss categoryIt explains that this problem has been solved. This includes: “You can receive individualized treatments based on individual goals, history, and preferences, such as combined oral medications and GLP-1.” The results were amazing... - Oral Medication: Customers have reported an average weight loss of 7.5 pounds by day 28 and 9 pounds by day 56. - Providing GLP-1: Customers report that they achieved an average weight loss of 9.3 pounds on day 28 and 12.5 pounds on day 56. User feedback is great too... “on day 5692% of oral drug users and GLP-1 use93% of people reported feeling healthier and improving their health, confidence, and mood.”

3. Competition: Hims, which leads the market, allows consumers to buy their productsIt is stated that they like it, and it suggests that they have gained market share from competitors. “Customers who have tried other traditional methods of losing weight have found success with our platform.” Hims suggests this is because “cost and availability” are barriers. Just in case, Hims also offers cheaper services.

4. Competition: High retention rate GLP-1 after the first month Only 13% of customers cancel their subscriptions, and the monthly retention rate is a staggering 87%. In contrast, 30% of patients who chose the “over-the-counter option” (i.e., a Hims competitor) stopped treatment after the first month. In other words, the 1-month retention rate is 70%.

GLP-1 This is the first time we've received excellent data from Hims regarding the product, and it's clear that the company is winning. Their products are more effective and more appealing. It's cheap, personalized, and convenient. Most importantly, consumers can lose weight safely. The white paper showcases the company's success in weight loss services. This was apparently created to show that the company should continue to provide this service even after the FDA's shortage has been resolved.